Mutational Resistance Expected with Mass Indiscriminate Nirsevimab Injection of Infants
434
1 comment
Analysis Demonstrates RSV Will Easily Mutate to Escape Monoclonal Antibodies
By Peter A. McCullough, MD, MPH
Quality journalism costs money to produce.
Free access provides up to 10 articles
Subscription options start at $5 per month
which is less than a Starbucks coffee!
Peter Gabriel, MD
"Publishing on TrialSite helped me secure a $20m research grant for my work."
Jona Savinda
"TrialSiteNews is my daily read for what is happening in the industry."
Lucas Van Der Hoven
"Objective, unbiased reporting on the latest news in medical research. I trust TrialSiteNews to give it to me straight."
Publish on TrialSite
TrialSiteNews
159 W Broadway, Suite 200
Salt Lake City, UT 84101
© 2025 - Trial Site News